developed by researchers at University college London with funding from the Biotechnology & Biological sciences Research Council (BBSRC),
"Fundamental bioscience research is vital to reveal the biological mechanisms underlying normal physiology across the lifespan.
The research jointly lead by Professor Christoph Hagemeyer, Head of the Vascular Biotechnology Laboratory at Baker IDI Heart and Diabetes Institute and Professor Frank Caruso,
the researchers used biotechnology to create the proteins in bacteria. The polymer can then either be molded using heat
biotechnology and medical treatments. The study appears September 21 in Nature Materials("Sequence Heuristics To Encode Phase Behaviour In Intrinsically Disordered Protein Polymers"."
and biotechnology applications,"said Ashutosh Chilkoti, chair of the Department of Biomedical engineering at Duke.""We can now,
a professor of biotechnology and bioengineering at The swiss Federal Institute of technology in Zurich, described this experiment as an legant proof of conceptthat could lead to greatly improved treatments for viral infection. entinel designer cells engineered with the DNA sense
Owing to the above-mentioned merits, SPR biosensing is an outstanding platform to boost technological progress in the areas of medicine and biotechnology.
and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
As they report Sept. 28 in Nature Biotechnology("Subangstrom single-molecule measurements of motor proteins using a nanopore),
"said Ellington, professor in the Department of Molecular Biosciences and member of the UT Center for Systems and Synthetic biology."
"What we found may have a big impact on future plant biotechnology research, "Dr Bally said."
including Lohitash Karumbaiah of the University of Georgia Regenerative Bioscience Center, has developed a brain-friendly extracellular matrix environment of neuronal cells that contain very little foreign material.
a biotechnologist who has helped developed stem cell-based treatments for ischemic diseases. The Hoope idea originated from a NASA camp where Damel team bested 80 other scientists in developing an impactful product.
Now, researchers from the Technical University of Dortmund in Germany have outlined in the journal Biotechnology Letters how they looked into
The study appears online April 6 in Nature Biotechnology.""The epigenome is associated everything with the genome other than the actual genetic sequence,
The research was supported by a University of California Discovery Biotechnology Award, the National institutes of health, Nanocav and the National Science Foundation n
"said Liang Xu, associate professor of molecular biosciences and corresponding author of the paper. The results hold promise for treating a broad array of cancers in people.
since Swedish biotech company Atlas Antibodies has shown interest in commercialising our findings, 'says Per-Henrik Edqvist.
Biopharmaceuticals, or biologics, are produced proteins by living cells. Proteins such as catalase are tens of thousands of times larger than the small molecules that make up traditional drugs.
"The discovery will also be useful in the biotechnology field for the development of a variety of marketable products
therefore necessary for the production of gibberellins--a mechanism that is highly relevant to the growth and development of plants,"says Poppenberger, Professor for the Biotechnology of Horticultural Crops.
The NAPA invention was licensed by Protea Biosciences Group, Inc, . and commercialized under the REDICHIP#name in June 2015.
Protea Biosciences Group, Inc. exclusively licensed the NAPA platform; in June 2015, the company commercialized the platform under the name of REDICHIP#i
This biotechnology method could also have similar applications to other low-concentration ions in solution.
and Biosciences Division, Heavy Element Chemistry Program under contract number DE-FG02-07er15865 to C. H
A major goal in biotechnology is to modify enzyme activity in order to carry out bespoke reactions. Current methods use genetic engineering to physically mutate enzymes.
and are already in use as a platform for other applications by biotechnology companies. The team is now investigating other enzymes that might benefit from monobody technology,
Next steps Biotechnologists know how to build the complex protein structures they find in nature, but the Stanford team took this further.
and different aspects are licensed to a biotechnology company in which Swartz has a founding interest. The approach is in its early stages
who also is an affiliate of the Berkeley National Laboratory's Physical Biosciences Division.""We've showed that we can greatly simplify the construction of these factories,
biotechnology and medical treatments.""The very simple design rules that we have discovered provide a powerful engineering tool for many biomedical
and biotechnology applications,"said Ashutosh Chilkoti, chair of the Department of Biomedical engineering at Duke.""We can now,
Zhang and his team at Rice's Bioscience Research Collaborative have become specialists in finding such needles in haystacks.
which Jin-Soo Kim points out,"paves the way for the widespread use of RNA-guided genome editing in plant biotechnology and agriculture."
This technological breakthrough hails opportunities for the development of smaller and cheaper sensors for various fields such as consumer electronics, information and communication technology, biotechnology and automotive.
where the specific marker shows in a few seconds,"explains project coordinator Dr. Marco Antonio Rite Palomares, director of the Biotechnology Center of the Tec de Monterrey FEMSA.
The director of FEMSA Biotechnology Center mentions that he considered using the camera phone to detect the marker in saliva,
The results were published today in two Nature Biotechnology reports. Sequencing the genome of Upland cotton (Gossypium hirsutum) will help breeders develop varieties of cotton that are equipped better to combat the pests,
are the lead authors in a study published in the April 20 edition of the journal Nature Biotechnology.
from the School of Biosciences. or the first time we have found a link airways inflammation,
But so far, scientists have had only access to a limited variety of biosensors that have little relevance to the biomanufacturing of valuable chemicals.
which we would rely on biomanufacturing for the clean production of chemical and pharmaceutical commodities, said Wyss Institute Founding Director Donald E. Ingber,
UED creates unprecedented opportunities for ultrafast science in a broad range of disciplines, from materials science to chemistry to the biosciences.
who earned his doctorate in biomedical engineering at Rutgers and now works in biopharmaceutical research and development at Glaxosmithkline.
Zhang and his team at Rice Bioscience Research Collaborative have become specialists in finding such needles in haystacks.
He used his research to launch three biotech companies centered on forensic science, fertility assessment and contraception methods.
and Differentiation in the Institute of Molecular and Cellular Biosciences have established a technique to isolate hipsc-derived liver progenitor cells (LPCS, cells
said Ellington, professor in the Department of Molecular Biosciences and member of the UT Center for Systems and Synthetic biology.
#Researchers Smash Records with Pig-to-Primate Organ transplants A biotech company is genetically engineering pigs so that their organs might work in people.
With the financial aid of a biotechnology executive whose daughter may need a lung transplant, U s. researchers have been shattering records in xenotransplantation,
The GM pigs are being produced in Blacksburg, Virginia, by Revivicor, a division of the biotechnology company United Therapeutics.
The technology might also pave the way to new biotech drugs. Nearly all such drugs
"says Sanjeev Mariathasan, a biologist Genentech, the biotech company behind the study. That's a big problem because drugs that are used normally against staph infections can take over four hours to work far longer than it takes for Staph bacteria to move into new cells,
biotechnology companies have made them as well. Genentech manufactured antibodies based on those the immune system makes to combat staph infections.
a biotechnology company that's working on a similar technique. Now, the researchers have to show that it works against multiple strains of bacteria as well,
#South korea to invest $300m in biotech The South korean Ministry of Science, ICT and Future Planning, the Ministry of Trade, Industry and Energy,
and other local agencies have announced plans to invest $300 million in fostering biotechnology over the course of 2015
As of 2012, it controlled just 1. 3 percent share in global biotechnology, the ministries said.
Biotechnology is quickly gaining popularity in South korea, the government said, with startups working on the area accounting for 13.7 percent of listed companies on the KOSDAW based on market value.
Venture capitalists invested a total of $225 million in biotech last year more than IT manufacturing's $150. 8 million and IT services'$131 million.
The government expects the global biotechnology market to see rapid growth, and expects it to dwarf the semiconductor, chemical,
RNA interference was identified more than a decade ago launching a new research field that has spawned a Nobel prize and new biotech firms.
and metal--and also suppressed biofilm formation in a study reported in Nature Biotechnology. But that's not All the team implanted medical-grade tubing
since the earliest days of endoscopy,"says Timo Cuntz, a member of the Project Group for Automation in Medicine and Biotechnology PAMB in Mannheim, a part of the Fraunhofer Institute for Manufacturing Engineering and Automation IPA.
'A new method developed at the Centre for Plant Biotechnology and Genomics (CBGP UPM-INIA) has shown that by the contact of a plant with a strain of the Colletotrichum tofieldiae microorganism previously isolated this plant can increase the number size
pageac=patente. jsp&idpatente=812) and there is an exclusive commercial patent license agreement with Plant Response Biotech S l. a spin-off company from the Universidad Politécnica de Madrid created in 2008 that focuses its work on the development
and biotechnology to precisely manipulate small volumes of fluids for use in applications such as enzymatic or DNA analysis pathogen detection clinical diagnostic testing and synthetic chemistry.
For the past 20 years microfluidics has been considered a boon for fields like biotechnology and engineering but has yet to be standardized
After developing Cellsqueeze at MIT, Sharei co-founded SQZ Biotech in 2013 to further develop and commercialize the platform.
Meanwhile, SQZ Biotech aims to reduce the footprint of its device, which could potentially lower the time
Gilead sciences, Inc.;the Howard hughes medical institute; the Department of Dermatology; and the Yale Comprehensive Cancer Center. Publication:
biotechs race to develop acute radiation drugs Since the nuclear crisis at the Fukushima Daiichi power station,
Now, however, several small biotech companies are racing to develop the first approved therapy for ARS,
#Where the bio-rubber meets the road My posts about biotechnology as it relates to agriculture tend to draw impassioned naysayers,
but surely here's a biotech application with which they can relate: a renewable fermentation process that seeks to act as a partial replacement for the an oil-based processes that goes into making synthetic rubber.
Biotech company Genencor, which is a division of Danisco, is more than one year into testing the commercial applications for
The work was published in Nature Biotechnology this week. And just last week Technology Review reported that Roche backed off its hostile takeover bid for Illumina,
Hitachi is also working on nanopore technology as are startups like Electronic Biosciences. Deamer says the idea of nanopore sequencing occurred to him in 1989 just three years after the first automated DNA sequencers were introduced.
which is manufactured by the American pharmaceutical company Amgen, have already been submitted to drugs regulators in Europe and the USA.
which is manufactured by the American pharmaceutical company Amgen, have already been submitted to drugs regulators in Europe and the USA.
both have an extensive background in biotechnology. At age 18, Erik Gatenholm started his first medical device company, manufacturing meniscus implants and other implants, such surgical meshes for ventral hernia repairs and wound dressings.
but also pave the way for more complex optical fiber structures that are able to host a variety of applications for industries ranging from telecommunications and aerospace to biotechnologies and more."
and Tong Wang, the other lead co-author of the paper and who also works with Li in the Biosciences department of Brookhaven.
who is also director of the NSF-NASA Center for Chemical Evolution and associate director of the Parker H. Petit Institute of Bioengineering and Bioscience,
Emiliana De Santis, who is developing the standard in NPL's Biotechnology Group, said:""Our ability to exploit self-assembly processes allows us to enable
biotechnology and nanobiotechnology for applications including targeted drug delivery. Chirality of an object is its property that allows it to be non-superimposable with its mirror image.
which also has an area of`Biotechnology and Drug Research of Biomedical engineering, Diagnosis and Treatment Equipment.
Earlier this month, MIT spinout Microchips Biotech partnered with a pharmaceutical giant to commercialize its wirelessly controlled, implantable,
Invented by Microchips Biotech cofounders Michael Cima, the David H. Koch Professor of Engineering, and Robert Langer, the David H. Koch Institute Professor, the microchips consist of hundreds of pinhead-sized reservoirs,
and osteoporosis. Now Microchips Biotech will begin co-developing microchips with Teva Pharmaceutical, the world largest producer of generic drugs,
Apart from providing convenience, Microchips Biotech says these microchips could also improve medication-prescription adherence a surprisingly costly issue in the United states. A 2012 report published in the Annals of Internal medicine estimated that Americans who don stick to prescriptions rack up $100 billion
Microchips Biotech will continue work on its flagship product, a birth-control microchip, backed by the Bill and Melinda Gates Foundation,
Cima, who now serves on the Microchips Biotech board of directors with Langer, sees this hormone-releasing microchip as one of the first implantable rtificial organsbecause it acts as a gland. lot of the therapies are trying to chemically trick the endocrine systems Cima says. e are doing that with this artificial organ we created.
For years, the technology underwent rigorous research and development at Microchips Biotech. But in 2011, Langer and Cima,
MEMS innovations Microchips Biotech made several innovations in the microelectromechanical systems (MEMS) manufacturing process to ensure the microchips could be commercialized.
To do so, Microchips Biotech modified a cold-welding ongue and grooveprocess. This meant depositing a soft,
Aurasense, Inc.,a biotechnology company that licensed the Nanoflare technology from Northwestern University, and EMD-Millipore, another biotech company, have commercialized Nanoflares.
There are now more than 1, 700 commercial forms of Nanoflares sold under the Smartflare? name in more than 230 countries.
biotechnology and instrumentation expertise to develop a portable, autonomous device that analyzes trace elements. The highly miniaturized microbial analysis machine,
Lead researcher Aydogan Ozcan, Howard hughes medical institute chancellor professor at UCLA, sat down with Bioscience Technology to talk about this advancement and its implications for resource-poor labs,
Ph d.,a postdoctoral fellow at the University Of Virginia School of medicine, told Bioscience Technology. ecently, we have seen that the areas that are surrounding the brain are full of immune cells, even in normal conditions,
Louveau told Bioscience Technology. he first question we are addressing is confirming that this structure exists in humans
However, fewer companies have worked on vaccines and drugs for the MERS virus, according to Reuters. Small biotech companies such as Greffex,
Earlier this month, MIT spinout Microchips Biotech partnered with a pharmaceutical giant to commercialize its wirelessly controlled, implantable,
Invented by Microchips Biotech cofounders Michael Cima, the David H. Koch Professor of Engineering, and Robert Langer, the David H. Koch Institute Professor, the microchips consist of hundreds of pinhead-sized reservoirs,
and osteoporosis. Now Microchips Biotech will begin co-developing microchips with Teva Pharmaceutical, the world largest producer of generic drugs,
Apart from providing convenience, Microchips Biotech said these microchips could also improve medication-prescription adherence a surprisingly costly issue in the United states. A 2012 report published in the Annals of Internal medicine estimated that Americans who don stick to prescriptions rack up $100 billion
Microchips Biotech will continue work on its flagship product, a birth-control microchip, backed by the Bill and Melinda Gates Foundation,
Cima, who now serves on the Microchips Biotech board of directors with Langer, sees this hormone-releasing microchip as one of the first implantable rtificial organsbecause it acts as a gland. lot of the therapies are trying to chemically trick the endocrine systems Cima said. e are doing that with this artificial organ we created.
For years, the technology underwent rigorous research and development at Microchips Biotech. But in 2011, Langer and Cima,
MEMS innovations Microchips Biotech made several innovations in the microelectromechanical systems (MEMS) manufacturing process to ensure the microchips could be commercialized.
To do so, Microchips Biotech modified a cold-welding ongue and grooveprocess. This meant depositing a soft,
#New Single-use Harvesting Technology for High Cell Density Cultures Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, has introduced Sartoclear Dynamics,
Sartorius Stedim Biotech has developed now this robust technology for biotech applications. Specially designed for cgmp processing
which is attractive for newcomers from emerging biotech markets. The ready-to-use clarification system enables harvesting of high cell density cultures up to 2, 000 liters 0
Anstie told Bioscience Technology. ather than sniffing out a variety of smells as a dog would,
Anstie told Bioscience Technology, ther conditions, although they have a clear molecular signature in the breath may be masked by the general complexity involved in getting a good repeatable sample.
a clinical stage biopharmaceutical company which owns the core T-cell receptor technology and funded the study.
one of the authors of the study and Professor of Biotechnology and Therapeutics at the Graduate school of Pharmaceutical Sciences at Osaka University. ecause the new patch is so easy to use,
the research team included Professor Vladimir Tsukruk from the Georgia Tech School of Materials science and engineering and Rajesh Naik, Biotechnology Lead and Tech Advisor of the Nanostructured and Biological Materials Branch
and by Georgia Tech Renewable Bioproducts Institute Fellowship. The content is solely the responsibility of the authors
#State Deficits to Shrink & Taxes Drop-Good News for Biotech Forecasters at the National Conference of State Legislatures2011 Legislative Summit expect a dramatic reduction of state deficits in the coming years,
Unfortunately these corporate tax cuts do not provide much-needed capital to small biotech companies because their lack of profits makes tax benefits unredeemable.
Most emerging biotech companies with promising scientific innovation are small, research-intensive and not yet profitable because they do not have approved an FDA product on the market.
Biotech start-ups generally struggle to raise capital to finance their research, and BIO advocates two important policies that enable them to continue critical R&d of advancements and breakthroughs.
The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.
I have noticed a promising trend the rise of open source drug R&d consortia that include large biotech
and biotech companies to develop better treatments most recently with Shire around rare diseases. These alliances leverage Boston Children research expertise and companiesdevelopment and commercialization capabilities.
generating creative initiatives from universities, tech transfer organizations, government and biotechs. BIO-X is an open innovation vehicle run by Uppsala BIO.
and small biotechs, offering to support their ideas through to proof of principle. or the proposals selected,
#Biotechnology Helps Meet Consumer Demand for Earth-Friendly Products Industrial biotechnology has its roots in cleaning up environmental hazards.
Today, biotechnology enables manufacturers to make sustainable products with renewable material, instead of oil, and to use less energy in the manufacturing process A recent Roundtable discussion hosted by the Industrial biotechnology Journal
and printed in its April edition features academic experts and executives from industrial biotechnology and consumer product companies discussing demand for sustainable products.
Visit Journal publisher Maryann Liebert at Booth 3617 in the BIO Exhibition. Consumers are looking for products that are safer,
Vice president of Global Sales and Applications for Dupont Industrial Biosciences. bout 80 percent of U s. consumers say they will buy green products
The $3. 5 trillion global chemicals market represents a significant opportunity for growth of industrial biotechnology that ultimately provides consumers a choice of safer, cleaner products f
Advances such as this show the promise of biotechnology to transform lives and enable patients who had relied previously on frequent,
and women at biotechnology companies across the world are working hard to advance every day. Read the full Wall street journal article here r
Industrial biotechnology continues to enable solutions to energy challenges and building a biobased economy is key to reducing dependence on foreign oil enhancing our nation economic and energy security.
Last week, the U s. Navy signed an agreement with biotech company Biodico to collaborate on developing advanced biofuels and bioenergy refineries throughout the globe for the U s. military.
The biopharmaceutical industry is an important contributor to U s. economic growth and sustainability, with more than 650,000 direct jobs (supporting a total of nearly 4 million jobs) and an economic output that totals more than $900 billion
As a result, gains and losses in the biopharmaceutical sector cascade across many important economic sectors in the U s. It is becoming clear,
however, that the U s. can no longer take its leadership in biopharmaceuticals or other knowledge-based industries for granted.
many of which are targeted to the biopharmaceutical industry and related sectors. Despite the short-term costs associated with these investments,
As a result, more and more, the U s. is competing globally to maintain its leadership position in biopharmaceuticals.
For purposes of this study, entitled The Biopharmaceutical Research and development Enterprise: Growth Platform for Economies Around the World, Battelle examined policies
and programs being implemented to promote the bioscience sector in 18 countries and the European union (E u.).These countries were selected because of their interest in growing an innovation economy.
In addition, countries selected include a mix of developed countries with an existing biopharmaceutical presence (Australia, Canada, France, Germany, Ireland, Israel, Italy, Japan, Sweden, the United kingdom UK,
and the E u. as a whole) and emerging countries that are targeting the biopharmaceutical sector (Brazil, Chile, China, Russia, Saudi arabia, Singapore, South africa, and South korea).
and capital, all of the countries examined are focusing on strategic components to grow their biopharmaceutical economy.
and programs to increase the economic footprint of the biopharmaceutical and related sectors in their own countries.
America innovative biopharmaceutical companies face increasing challenges, ranging from the cost and increased complexity of bringing new medicines to patients, the prospect of attracting
Just as other countries have drawn lessons from the growth of the U s. biopharmaceutical sector so too can the U s. learn from other countries that are strategically
Alicia Jackson, the deputy director of Darpa Biological Technologies Office In virginia, made comments alluding to the technology at a biotech conference on Monday. or the first time
Aurasense, Inc.,a biotechnology company that licensed the Nanoflare technology from the university, and EMD-Millipore, another biotech company, have commercialized Nanoflares.
There are now more than 1, 700 commercial forms of Nanoflares sold under the Smartflare name in more than 230 countries.
"The acquisition of NPS Pharma is a significant step in advancing Shire's strategy to become a leading biotechnology company, Shire CEO Flemming Ornskov, M d,
Amgen markets cinacalcet HCL as Sensipar in the U s. and as Mimpara in the EU;
and the Biotechnology industry Organization (BIO) ignaled support for sharing clinical trial data beyond recent industry norms,
Express Scriptsindependent Pharmacy & Therapeutics Committee concluded that Viekira Pak was at least clinically equivalent to two Gilead sciences drugs, Harvoni (ledipasvir and sofosbuvir) and Sovaldi (sofosbuvir.
Representatives of two other top-selling cancer drug developers, Celgene and Amgen, at deadline had responded not to GEN queries on indication pricing
according to Michael Egholm, president of Pall Biopharmaceuticals. The AWS technology works by applying acoustic forces across a flow channel to generate a three-dimensional standing wave.
but accelerating, a phenomenon that is reflected in the timing of biopharmaceutical product launches: Since the first biopharmaceutical drug Humulin was launched in 1982 to the beginning of this decade (between 1982 and 2009 27 year period),
there were 117 biopharmaceutical approvals. That an impressive number, but there have been 67 approvals between 2010 and 2014 four year period.
Roughly speaking, biopharmaceutical product launches increased from around 4 to nearly 17 approvals per year. Biopharmaceutical production is increasing not only through the introduction of novel therapeutics,
but also through the introduction of biosimilars or generic biopharmaceuticals, which can be manufactured by several companies.
The market for cell cultures is expected to grow rapidly alongside biopharmaceuticals and with significant evolution in culture technology.
Cell Line Trends Many biopharmaceuticals are produced by bacteria especially the species Escherichia coli and Bacillus subtilis. E coli has been studied in microbiology laboratories for many years
and was the first organism to have its entire genome mapped. It is inexpensive to cultivate,
it replicates quickly, and it serves as a good model organismhat is, it provides an example of how other similar life forms will behaveuch as how they grow
Bacterial culture is the workhorse of the biotechnology industry. Animal cells are much more fragile than yeast and bacterial cells.
The rising stakes and production levels of companies active in biopharmaceuticals have dictated improved reproducibility or consistency in product;
The biopharmaceutical industry shift away from animal-derived culture products is expected to continue, particularly given the ascension of mammalian cell lines in biopharmaceutical production.
Serum-free media is the more complex composition designed for universal use in culturing mammalian cell lines.
Working and Master Cell Banks Once a biopharmaceutical company obtains a beginning cell bank from a cell culture collection,
in particular single-use disposable production systems, are dramatically lowering building costs of biomanufacturing plants. In the near term
In the longer term, biomanufacturing expansion will extend into South america, Eastern europe, and Africa. Market Drivers An important driver of the cell culture market is the production of seasonal influenza vaccines,
and a Biotechnology and Biological sciences Research Council award, was published in the Science Translational Medicine journal in April.
A few years back while working as a postdoc in Vienna at the Institute of Molecular Biotechnology (IMBA
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011